ScholarIQanswers from OpenAlex & ORCID
Robert E. Coleman
ResearcherPublications, citations & collaboration network
Robert E. Coleman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert E. Coleman have?
ScholarIQindexed works
Robert E. Coleman has 767 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert E. Coleman have?
ScholarIQcitation count
Robert E. Coleman has 59,130 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert E. Coleman?
ScholarIQh-index
Robert E. Coleman has an h-index of 118 in OpenAlex.
What is the i10-index of Robert E. Coleman?
ScholarIQi10-index
Robert E. Coleman has an i10-index of 459 in OpenAlex.
What is the ORCID of Robert E. Coleman?
ScholarIQorcid
The ORCID for Robert E. Coleman is on the source record.
What is the OpenAlex record for Robert E. Coleman?
ScholarIQopenalex
The OpenAlex for Robert E. Coleman is on the source record.
What are the most-cited papers on Robert E. Coleman?
ScholarIQmost cited works
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
R. Charles Coombes, Emma Hall, Lorna J. Gibson, Robert Paridaens, Jacek Jassem, T. Delozier, Stephen E. Jones, Isabel Álvarez, Gianfilippo Bertelli, Olaf Ortmann, Alan S. Coates, Emilio Bajetta, David Dodwell, Robert E. Coleman, Lesley Fallowfield, E. Mickiewicz, Jørn Andersen, Per Eystein Lønning, Giorgio Cocconi, Alan L. Stewart, Nick Stuart, Claire Snowdon, M. Carpentieri, Giorgio Massimini, Judith M. Bliss
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard
Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
Laura Biganzoli, Tanja Čufer, P.F. Bruning, Robert E. Coleman, Luc Duchateau, A H Calvert, Teresa Gamucci, Chris Twelves, P. Fargeot, Ron Epelbaum, Caroline Lohrisch, M. Piccart